The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-10 and is reviewed periodically as new material appears.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
==== Nested PCR ==== The use of nested polymerase chain reaction (nested PCR) was evaluated to determine sex by detecting a Y chromosome specific signal in the cffDNA from maternal plasma. Nested PCR detected 53 of 55 male fetuses. The cffDNA from the plasma of 3 of 25 women with female fetuses contained the Y chromosome-specific signal. The sensitivity of nested PCR in this experiment was 96 percent. The specificity was 88 percent.
The most common side effect is eye irritation felt as stinging or burning, which occurs in up to a third of patients. Blepharoconjunctivitis occurs in up to 5% of patients. Rarer adverse effects include keratitis, edema and increased lacrimation. Allergies are rare, but seem to be more common than under the related drug timolol. If the substance reaches the nasal mucosa via the tear duct, it can be absorbed into the bloodstream and cause systemic side effects. These include orthostatic hypotension (low blood pressure) and other effects on the heart and circulatory system, breathing problems in people with asthma, and skin symptoms such as itching and aggravation of psoriasis.
16 November – In a statement to the Scottish Parliament, Health Secretary Michael Matheson admits the cause of his £11,000 roaming charges bill came from his sons watching football on his parliamentary iPad while the family was on holiday in Morocco. Matheson confirms he has repaid the money and referred himself to the parliamentary watchdog. 17 November – A number of motorists have had their Glasgow Low Emission Zone fines cancelled after a tribunal ruled they were unenforceable due to a "procedural error" made by Glasgow City Council. The Scottish Government publishes its plans for European Union membership in an independent Scotland. 22 November – Petroineos announces to repurpose Grangemouth oil refinery, Scotland's only oil refinery, as a fuels import terminal with the loss of 400 jobs. The McDonald's fast food outlet in Fort William says it has had to ban under 18s from the premises after 6.00pm because of verbal abuse targeted at its staff. 23 November – The Scottish Parliament Corporate Body confirms it has launched an investigation into Health Secretary Michael Matheson's £11,000 data roaming bill. 24 November – Former First Minister Alex Salmond launches a fresh legal case against the Scottish Government over its mishandling of harassment allegations against him. Universities Scotland adopts a new policy that requires potential students offered a place at a university in Scotland to declare any charges for violent offences. 25 November – A police officer is taken to hospital after a civil disturbance breaks out in the East Ayrshire village of Auchinleck.
=== Niche uses === Triethylamine is commonly used in the production of anionic polyurethane dispersions (resins dispersed in water rather than solvents) as a neutralizing agent. Triethylamine is used to give salts of various carboxylic acid-containing pesticides, e.g. Triclopyr and 2,4-dichlorophenoxyacetic acid. Triethylamine is the active ingredient in FlyNap, a product for anesthetizing fruit flies. It is also used in mosquito and vector control labs to anesthetize mosquitoes. This is done to preserve any viral material that might be present during species identification. The bicarbonate salt of triethylamine (often abbreviated TEAB, triethylammonium bicarbonate [(CH3CH2)3NH]+HCO−3) is useful in reverse phase chromatography, often in a gradient to purify nucleotides and other biomolecules. Triethylamine was discovered by the Germans during the early 1940s to be hypergolic in combination with nitric acid, and was used as a component in the German Wasserfall rocket. The Soviet Scud missile used TG-02, a mixture of 50% xylidine and 50% triethylamine as a starting fluid to ignite its rocket engine.
=== SSAP === The SSAP (Sequential Structure Alignment Program) method uses double dynamic programming to produce a structural alignment based on atom-to-atom vectors in structure space. Instead of the alpha carbons typically used in structural alignment, SSAP constructs its vectors from the beta carbons for all residues except glycine, a method which thus takes into account the rotameric state of each residue as well as its location along the backbone. SSAP works by first constructing a series of inter-residue distance vectors between each residue and its nearest non-contiguous neighbors on each protein. A series of matrices are then constructed containing the vector differences between neighbors for each pair of residues for which vectors were constructed. Dynamic programming applied to each resulting matrix determines a series of optimal local alignments which are then summed into a "summary" matrix to which dynamic programming is applied again to determine the overall structural alignment. SSAP originally produced only pairwise alignments but has since been extended to multiple alignments as well. It has been applied in an all-to-all fashion to produce a hierarchical fold classification scheme known as CATH (Class, Architecture, Topology, Homology), which has been used to construct the CATH Protein Structure Classification database.
Sources: en.wikipedia.org
=== GC–tandem MS === When a second phase of mass fragmentation is added, for example using a second quadrupole in a quadrupole instrument, it is called tandem MS (MS/MS). MS/MS can sometimes be used to quantitate low levels of target compounds in the presence of a high sample matrix background. The first quadrupole (Q1) is connected with a collision cell (Q2) and another quadrupole (Q3). Both quadrupoles can be used in scanning or static mode, depending on the type of MS/MS analysis being performed. Types of analysis include product ion scan, precursor ion scan, selected reaction monitoring (SRM) (sometimes referred to as multiple reaction monitoring (MRM)) and neutral loss scan. For example: When Q1 is in static mode (looking at one mass only as in SIM), and Q3 is in scanning mode, one obtains a so-called product ion spectrum (also called "daughter spectrum"). From this spectrum, one can select a prominent product ion which can be the product ion for the chosen precursor ion. The pair is called a "transition" and forms the basis for SRM. SRM is highly specific and virtually eliminates matrix background.
Some supplements may help prevent migraine frequency or severity, including riboflavin (vitamin B2), vitamin D, magnesium, alpha-lipoic acid, and coenzyme Q10. Omega-3 fatty acids do not seem to help.
=== Acquired hypofibrinogenemia === Acquired hypofibrinogenemia is a deficiency in circulating fibrinogen due to excessive consumption that may occur as a result of trauma, certain phases of disseminated intravascular coagulation, and sepsis. It may also occur as a result of hemodilution as a result of blood losses and/or transfusions with packed red blood cells or other fibrinogen-poor whole blood replacements. The low fibrinogen level in hemorrhagic fever caused by crimean-congo hemorrhagic fever virus is associated with high mortality rate.
==== European Chips Act ==== In February 2022, the European Union introduced its own European Chips Act initiative. The background of the initiative would be the objective of European strategic autonomy. The EU's initiative puts forward subsidies of 30 billion euros to encourage manufacturing of semiconductors in the EU. The US company Intel is one beneficiary of the initiative. The US and European chips acts raise concerns of protectionism and a risk of a subsidies "race to the bottom".
Zero – the Olmec independently invented the concept of zero. The second earliest found instance of the use of zero—in Mesoamerica—has been dated to 32 BCE by the Epi-Olmec culture. This date has been arrived at based on the Long Count date on Stela C at Tres Zapotes. The symbol used for "zero" is a shell glyph, which is seen on the stone carving. Although the Olmec didn't leave behind any statues or reliefs with a "zero" glyph, the use of the Long Count calendar requires the knowledge of this concept since it is based on a (vigesimal) place-value number system.
Sources: en.wikipedia.org
The insulin receptor (IR) is a transmembrane receptor that is activated by insulin, IGF-I, IGF-II and belongs to the large class of receptor tyrosine kinase. Metabolically, the insulin receptor plays a key role in the regulation of glucose homeostasis; a functional process that under degenerate conditions may result in a range of clinical manifestations including diabetes and cancer. Insulin signalling controls access to blood glucose in body cells. When insulin falls, especially in those with high insulin sensitivity, body cells begin only to have access to lipids that do not require transport across the membrane. So, in this way, insulin is the key regulator of fat metabolism as well. Biochemically, the insulin receptor is encoded by a single gene INSR, from which alternate splicing during transcription results in either IR-A or IR-B isoforms. Downstream post-translational events of either isoform result in the formation of a proteolytically cleaved α and β subunit, which upon combination are ultimately capable of homo or hetero-dimerisation to produce the ≈320 kDa disulfide-linked transmembrane insulin receptor.
=== Contestants === 1st - Blayre Wright, Bakery Owner from Lancaster, Pennsylavania 2/3/4th - Zac Mercer, Bakery Owner from Denver, Colorado 2/3/4th - Lauren Rodgers, Bakery Owner from Olympia, Washington 2/3/4th - Jill Davis, Bakery Owner from Owosso, Michigan 5th - Kristi Descher, Pastry Chef from Valencia, California 6th - Alexey Ivanov, Home Baker from Brooklyn, New York 7th - Lola Forbes, Bakery Co-Owner from Mesa, Arizona 8th - Maricsa Trejo, Bakery Owner from Richardson, Texas 9th - Justin Dominguez, Bakery Owner and Cake Artist from San Antonio, Texas 9th - Margarita Garcia, Pastry Chef from Miami, Florida 11th - Marcus Brackett, Self-Taught Baker from Rockville, Maryland 12th - AJ DeDiego, Home Baker from Atlanta, Georgia
== Overview == One of the distinguishing features of ColdFusion is its associated scripting language, ColdFusion Markup Language (CFML). CFML compares to the scripting components of ASP, JSP, and PHP in purpose and features, but its tag syntax more closely resembles HTML, while its script syntax resembles JavaScript. ColdFusion is often used synonymously with CFML, but there are additional CFML application servers besides ColdFusion, and ColdFusion supports programming languages other than CFML, such as server-side Actionscript and embedded scripts that can be written in a JavaScript-like language known as CFScript. Originally a product of Allaire and released on July 2, 1995, ColdFusion was developed by brothers Joseph J. Allaire and Jeremy Allaire. In 2001 Allaire was acquired by Macromedia, which in turn was acquired by Adobe Systems Inc in 2005. ColdFusion is most often used for data-driven websites or intranets, but can also be used to generate remote services such as REST services, WebSockets, SOAP web services or Flash remoting. It is especially well-suited as the server-side technology to the client-side ajax. ColdFusion can also handle asynchronous events such as SMS and instant messaging via its gateway interface, available in ColdFusion MX 7 Enterprise Edition.
== Clinical significance == The proteasome and its subunits are of clinical significance for at least two reasons: (1) a compromised complex assembly or a dysfunctional proteasome can be associated with the underlying pathophysiology of specific diseases, and (2) they can be exploited as drug targets for therapeutic interventions. More recently, more effort has been made to consider the proteasome for the development of novel diagnostic markers and strategies. An improved and comprehensive understanding of the pathophysiology of the proteasome should lead to clinical applications in the future. The proteasomes form a pivotal component for the ubiquitin–proteasome system (UPS) and corresponding cellular Protein Quality Control (PQC). Protein ubiquitination and subsequent proteolysis and degradation by the proteasome are important mechanisms in the regulation of the cell cycle, cell growth and differentiation, gene transcription, signal transduction and apoptosis. Proteasome defects lead to reduced proteolytic activity and the accumulation of damaged or misfolded proteins, which may contribute to neurodegenerative disease, cardiovascular diseases, inflammatory responses and autoimmune diseases, and systemic DNA damage responses leading to malignancies.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.